Stockreport

How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin's Rare Disease Portfolio [Yahoo! Finance]

Amicus Therapeutics, Inc.  (FOLD) 
Last amicus therapeutics, inc. earnings: 11/11 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.amicusrx.com/investor-relations
PDF Amicus Therapeutics' fair value estimate has been maintained at US$14.50 per share, with analysts keeping the central price target steady despite several small model tw [Read more]